2WK3

Crystal structure of human insulin-degrading enzyme in complex with amyloid-beta (1-42)

Summary for 2WK3

• Entry DOI: 10.2210/pdb2wk3/pdb
• Related: 1AAP 1AMB 1AMC 1AML 1BA4 1BA6 1BJB 1BJC 1BRC 1CA0 1HZ3 1IYT 1MWP 1OWT 1QCM 1QWP 1QXC 1QYT 1RW6 1TAW 1TKN 1UO7 1UO8 1UOA 1UOI 1X11 1ZE7 1ZE9 1ZJD 2BEG 2BOM 2BP4 2JBU 2JG4 2WBY 2WC0
• Descriptor: INSULIN DEGRADING ENZYME, BETA-AMYLOID PROTEIN 42, ZINC ION, ... (4 entities in total)
• Functional Keywords: metal-binding, metalloprotease, ide, protease, hydrolase, amyloid-beta (1-42)
• Biological source: HOMO SAPIENS (HUMAN); More
• Cellular location: Cytoplasm: P14735; Membrane; Single-pass type I membrane protein: P05067
• Total number of polymer chains: 4
• Total formula weight: 245108.32

Authors

Guo, Q.,Tang, W.J. (deposition date: 2009-06-05, release date: 2009-11-03, Last modification date: 2024-05-08)

Primary citation

Guo, Q.,Manolopoulou, M.,Bian, Y.,Schilling, A.B.,Tang, W.J.
Molecular Basis for the Recognition and Cleavages of Igf-II, Tgf-Alpha, and Amylin by Human Insulin Degrading Enzyme.
J.Mol.Biol., 395:430-, 2010

PubMed Abstract: Insulin-degrading enzyme (IDE) is involved in the clearance of many bioactive peptide substrates, including insulin and amyloid-beta, peptides vital to the development of diabetes and Alzheimer's disease, respectively. IDE can also rapidly degrade hormones that are held together by intramolecular disulfide bond(s) without their reduction. Furthermore, IDE exhibits a remarkable ability to preferentially degrade structurally similar peptides such as the selective degradation of insulin-like growth factor (IGF)-II and transforming growth factor-alpha (TGF-alpha) over IGF-I and epidermal growth factor, respectively. Here, we used high-accuracy mass spectrometry to identify the cleavage sites of human IGF-II, TGF-alpha, amylin, reduced amylin, and amyloid-beta by human IDE. We also determined the structures of human IDE-IGF-II and IDE-TGF-alpha at 2.3 A and IDE-amylin at 2.9 A. We found that IDE cleaves its substrates at multiple sites in a biased stochastic manner. Furthermore, the presence of a disulfide bond in amylin allows IDE to cut at an additional site in the middle of the peptide (amino acids 18-19). Our amylin-bound IDE structure offers insight into how the structural constraint from a disulfide bond in amylin can alter IDE cleavage sites. Together with NMR structures of amylin and the IGF and epidermal growth factor families, our work also reveals the structural basis of how the high dipole moment of substrates complements the charge distribution of the IDE catalytic chamber for the substrate selectivity. In addition, we show how the ability of substrates to properly anchor their N-terminus to the exosite of IDE and undergo a conformational switch upon binding to the catalytic chamber of IDE can also contribute to the selective degradation of structurally related growth factors.

PubMed: 19896952
DOI: 10.1016/J.JMB.2009.10.072

Experimental method

X-RAY DIFFRACTION (2.59 Å)